Arca
Skip to content
Tools
Tools

Acute coronary syndrome

Drug research and approvals for acute coronary syndrome: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 210 studies of acute coronary syndrome are recruiting on ClinicalTrials.gov, Health Canada has authorized 11 drug trials for it since 2013, and the EU has 9 authorised medicines for it.

  • Recruiting worldwide: 210
  • Trials authorized in Canada: 11
  • FDA orphan approvals: 0
  • EU medicines: 9

Recruiting now

Newest posted first, of 210 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 7

Phase 3 12 of 24

Phase 2 12 of 15

Phase 1 or earlier 10

How its trials ended

1,335 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 303 whose ending is known, 47% met their primary endpoint, 17% missed it and 36% stopped early.

  • Completed, result not reported51238%
  • Status unknown29222%
  • Ongoing22817%
  • Met its primary endpoint14311%
  • Missed its primary endpoint504%
  • Stopped: other or unclear484%
  • Stopped: enrollment or feasibility353%
  • Stopped: sponsor or business decision161%
  • Stopped: lack of efficacy71%
  • Stopped: funding3<1%
  • Stopped: safety1<1%

Trials authorized in Canada

The 10 newest of 11; search them all in Canada trials
Sep 12, 2025A randomized, double-blind, placebo-controlled study to evaluate efficacy and safety of early in hospital initiation of inclisiran treatment in patients with…Inclisiran (KJX839)Novartis PharmaceuticalsOngoing
Apr 25, 2023A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined…Dalcetrapib (RO4607381)Dalcor Pharmaceuticals Canada Inc.Ongoing
Apr 12, 2023A phase 3, randomized, double-blind, placebo-controlled, event-driven study to demonstrate the efficacy and safety of milvexian, an oral factor xia inhibitor,…Milvexian (JNJ-70033093, BMS-986177)Johnson & JohnsonClosed
Sep 15, 2021Open-label, sequential-dose escalation/de-escalation trial testing MT1002 in patients undergoing pci due to acute coronary syndrome with nstemiMT1002Shaanxi Micot Technology Co. LtdOngoing
Sep 30, 2016Multiple-dose, dose-finding placebo controlled double-blind randomized trial to compare the effect of treatment on plaque burden determined by ivus; evaluate…MDCO-216MedicinesPending
Jan 20, 2016A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined…DalcetrapibDalcor Pharma Ukltd, Swiss BranchOngoing
Aug 27, 2015A phase Ib study of duvalumab (MEDI-4736) with or without tremelimumab in patients with advanced incurable solid malignancies receiving standard chemotherapy…MEDI4736 / Tremelimumab / Abraxane / CarboplatinNcic Clinical Trials Group Queens UniversityOngoing
Aug 26, 2015A placebo-controlled, double-blind, randomized trial to compare the effect of treatment on plaque burden as determined by ivus and to evaluate the efficacy,…MDCO-216 (dimeric rapoa-im/popc),…MedicinesOngoing
May 29, 2015An open-label, 2 x 2 factorial, randomized controlled, clinical trial to evaluate the safety of apixaban vs. vitamin k antagonist and aspirin vs. aspirin…Eliquis (apixaban; BMS-562247)/ Acetylsalicylic acidBristol-Myers SquibbClosed
May 6, 2015A randomized, double-blind, double-dummy, active-controlled, parallel-group, multicenter study to compare the safety of rivaroxaban versus acetylsalicylic acid…Xarelto (rivaroxaban, bay 59-7939)/ Aspirin (acetylsalicylic acid)Johnson & JohnsonClosed

Medicines authorised in the EU

Newest first
Nov 16, 2020Rivaroxaban AccordRivaroxaban · genericAccord Healthcare S.L.U.EMA ↗
Jan 9, 2020Clopidogrel / Acetylsalicylic acid Viatris (previously Clopidogrel / Acetylsalicylic acid Mylan)Clopidogrel; acetylsalicylic acid · genericMylan Pharmaceuticals LimitedEMA ↗
May 15, 2018Prasugrel Viatris (previously Prasugrel Mylan)Prasugrel · genericViatris LimitedEMA ↗
Mar 23, 2015KengrexalCangrelorChiesi Farmaceutici S.p.A.EMA ↗
Mar 14, 2010DuoPlavinClopidogrel; acetylsalicylic acidSanofi Winthrop IndustrieEMA ↗
Mar 14, 2010Clopidogrel/Acetylsalicylic acid Zentiva (previously DuoCover)Clopidogrel; acetylsalicylic acidSanofi-Aventis GroupeEMA ↗
Jul 27, 2009Clopidogrel Teva (hydrogen sulphate)Clopidogrel · genericTeva Pharma B.V.EMA ↗
Feb 24, 2009EfientPrasugrelSubstipharmEMA ↗
Sep 30, 2008XareltoRivaroxabanBayer AGEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.